88
Participants
Start Date
December 23, 2013
Primary Completion Date
December 12, 2017
Study Completion Date
October 14, 2021
Tepotinib
Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
Gefitinib
Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
Pemetrexed
Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Cisplatin
Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Carboplatin
Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Jilin Cancer Hospital, Changchun
Jilin University, Changchun
Fuzhou General Hospital, Fuzhou
Guangdong Provincial People's Hospital, Guangzhou
Sir Run Run Shaw Hospital Cardiology, Hangzhou
The First Affiliated Hospital of College of Medicine, Hangzhou
Shanghai Chest Hospital, Shanghai
Tongji Hospital, Wuhan
Fourth Military Medical University, Xi'an
Zhejiang Cancer Hospital, Zhejiang
Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario, Catanzaro
IEO Istituto Europeo di Oncologia, Milan
University Malaya Medical Centre, Kuala Lumpur
Beacon International Specialist Centre Sdn Bhd, Petaling Jaya
National Cancer Center, Singapore
National University Hospital, Singapore
Raffles Hospital, Singapore
Chungbuk National University Hospital, Cheongju-si
Kyungpook National University Hospital, Daegu
Chonnam National University Hwasun Hospital, Hwasun
CHA Bundang Medical Center, CHA University, Seongnam-si
Seoul National University Bundang Hospital, Seongnam-si
Severance Hospital Yonsei University Health System, Seongnam-si
Asan medical Centre, Seoul
Gangnam Severance Hospital Yonsei University, Seoul
Korea University Anam Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National Universtiy Hospital, Seoul
The Catholic University of Korea St Mary s Hospital, Seoul
The Catholic University of Korea St. Vincent's Hospital, Suwon
Hospital Universitari Vall d'Hebron, Barcelona
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Clinico Universitario, Valencia
Hospital Alvaro Cunqueiro, Vigo
Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung City
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Tri-Service General Hospital, Taipei
Chang Gung Memorial Hospital Linkou, Taoyuan District
Merck KGaA, Darmstadt, Germany
INDUSTRY